25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients. 1979

G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani

The effects of 25-OHD3 on renal osteodystrophy have been studied in 6 patients on maintenance haemodialysis. Administration of 25-OHD3, 50 microgram/day, did not improve biochemical data and intestinal absorption of calcium. With a dose of 100 microgram/day in all patients an increase in blood calcium levels eventually reaching hypercalcemic values was observed. In two cases a fall in alkaline phosphatase toward normal values was noted. In the same cases the treatment-induced hyperphosphatemia, uncontrolled by AI(OH)3 supplementation and similarly high iPTH levels were observed. In two cases repeated bone biopsy following 8 months treatment and not show substantial improvement of bone lesions. In one case addition of 1,25-(OH)2D3 to the treatment with 25-OHD3 led to a more rapid improvement in biochemical parameters and iPTH serum levels. Doses of 25-OHD3 capable to correct blood calcium levels and intestinal absorption of calcium, may have minimal benefit on the osteitis fibrosa component of the bone lesion.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012080 Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. Renal Osteodystrophy,Renal Rickets,Rickets, Renal,CKD-MBD,Osteodystrophy, Renal,Chronic Kidney Disease Mineral and Bone Disorder,Osteodystrophies, Renal,Renal Osteodystrophies
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
November 1970, Archives of internal medicine,
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
April 1977, Lancet (London, England),
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
February 1979, Kidney international,
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
December 1974, Journal d'urologie et de nephrologie,
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
January 1980, International urology and nephrology,
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
May 1977, Calcified tissue research,
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
February 1982, Mineral and electrolyte metabolism,
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
May 1977, Calcified tissue research,
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
September 1975, The Journal of clinical investigation,
G Coen, and M Taccone-Gallucci, and E Bonucci, and G Bianchini, and G Gallucci, and G Lucentini, and M C Matteucci, and S Picca, and C U Casciani
August 1977, The Journal of clinical investigation,
Copied contents to your clipboard!